drugset
drugset / Trial / NCT04880616

Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor

NCT04880616 ↗

Phase 2 Completed 31 enrolled Neurocrine Biosciences
RandomizedCrossoverTriple-blindTreatment

Summary

The main objective of this study is to evaluate the efficacy, safety, and tolerability of NBI-827104 in adults with essential tremor.

Timeline

Start
2021-04-20
Primary completion
2022-05-25
Completion
2022-06-08

Drugs

EvaluationDrugModalityDoseRoute
Subject APINOCALTAMIDE Small molecule — Oral

Indications

essential tremor